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Aging is the main risk factor for many chronic degenerative diseases and cancer. Increased
senescent cell burden in various tissues is a major contributor to aging and age-related
diseases. Recently, a new class of drugs termed senolytics were demonstrated to extending
healthspan, reducing frailty and improving stem cell function in multiple murine models of
aging. To identify novel and more optimal senotherapeutic drugs and combinations, we
established a senescence associated β-galactosidase assay as a screening platform to rapidly
identify drugs that speciﬁcally affect senescent cells. We used primary Ercc1−/− murine
embryonic ﬁbroblasts with reduced DNA repair capacity, which senesce rapidly if grown at
atmospheric oxygen. This platform was used to screen a small library of compounds that
regulate autophagy, identifying two inhibitors of the HSP90 chaperone family as having
signiﬁcant senolytic activity in mouse and human cells. Treatment of Ercc1−/Δ mice, a mouse
model of a human progeroid syndrome, with the HSP90 inhibitor 17-DMAG extended
healthspan, delayed the onset of several age-related symptoms and reduced p16INK4a
expression. These results demonstrate the utility of our screening platform to identify
senotherapeutic agents as well as identiﬁed HSP90 inhibitors as a promising new class of
senolytic drugs.
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Aging is associated with an inevitable and progressiveloss of the ability of tissues to recover from stress.As a consequence, the incidence of chronic degenerative
diseases increases exponentially starting at the age of 65. This
includes neurodegeneration, cardiovascular disease, diabetes,
osteoarthritis, cancers and osteoporosis1–4. More than 90% of
people over 65 years of age have at least one chronic disease,
while 75% have at least two5. Thus, it is imperative to ﬁnd a way
to therapeutically target the process of aging to compress the
period of functional decline in old age6, 7. Such a therapeutic
approach would simultaneously prevent, delay, or alleviate
multiple diseases of old age. Indeed, several drugs, including
rapamycin, acarbose, 17α-estradiol and nordihydroguaiaretic acid
(NDGA) have been shown to extend the lifespan of mice by the
National Institute on Aging Interventions Testing Program8, 9
and metformin will be tested in a clinical trial for its ability to
delay onset of multiple age-related diseases (National Clinical
Trial number: NCT02432287)10, 11.
Replicative senescence is a cellular program preventing
further cell divisions once telomeres become critically short12.
Senescence also can be induced by cellular stress, including
oxidative and genotoxic stresses, or by activation of certain
oncogenes2, 13. Senescent cells secrete pro-inﬂammatory factors,
metalloproteinases, and other proteins, collectively termed the
senescence-associated secretory phenotype (SASP)14. With
chronological aging, there is an accumulation of senescent cells in
mammals15, 16. This is thought to drive senescence of neighboring
cells via the SASP and the functional decline of tissues17, 18.
In support of this, selective killing of p16INK4a-positive
senescent cells extends healthspan in a transgenic mouse model
(INK-ATTAC mice) of accelerated aging19. We found that
clearing senescent cells from aged INK-ATTAC mice improves
age-related changes in metabolic function20. Others subsequently
demonstrated that chronic clearance of p16INK4a-positive cells in
adult mice extends the median lifespan21. Clearance of senescent
cells in versions of this genetic model restored vascular
reactivity22, stabilized atherosclerotic plaques23, improved
pulmonary function24, alleviated osteoarthritis25, and improved
fatty liver disease26. Thus, the increase in cellular senescence
that occurs with aging appears to play a major role in driving
life-limiting age-related diseases4, 14, 27, 28.
Therefore, therapeutic approaches to speciﬁcally kill senescent
cells have the potential to extend healthspan and lifespan. Indeed,
using a bioinformatics approach, we recently identiﬁed several
pro-survival pathways, including the Bcl-2/Bcl-XL, p53/p21,
PI3K/AKT, and serpine anti-apoptotic pathways that, when
inhibited, result in death of senescent murine and human cells.
A combination of the drugs dasatinib and quercetin, which target
several of these pro-survival pathways, induce death speciﬁcally in
senescent murine and human cells in vitro, as well as enhance
cardiovascular function in aged mice, treadmill endurance
in radiation-exposed mice, and decrease frailty, neurologic
dysfunction and bone loss in progeroid mice29. Furthermore,
dasatinib and quercetin reduce senescent cell burden and aortic
calciﬁcation in the aortae of atherosclerotic apoE−/− mice
and improve lung function in the mouse model of idiopathic
pulmonary ﬁbrosis22. Interestingly, the natural compounds
ﬁsetin, a quercetin-related ﬂavonoid, and piperlongumine
also have senolytic activity in certain cell types in culture30, 31.
Similarly, we and others also demonstrated that several inhibitors
of Bcl-2 family members like navitoclax (ABT263), A1331852 and
A1155463 are senolytic in some, but not all cell types32, 33.
Navitoclax treatment of mice not only reduced senescent cell
burden but also alleviates radiation-induced hematopoietic stem
cell dysfunction33. In addition, a FOXO4-interacting peptide that
blocks an association with p53 recently was demonstrated to
induce apoptosis in senescent cells and improve ﬁtness, hair
growth and kidney function in old mice34. Despite these exciting
results, demonstrating the in vivo efﬁcacy of senolytics in
improving healthspan, candidate drug, and bioinformatics
approaches do not allow for identiﬁcation of novel and poten-
tially more effective chemical entities that target senescent cells35.
Here, we describe the development of a novel screening
platform to identify senotherapeutics, drugs that either suppress
senescence (senomorphics) or selectively kill senescent cells
(senolytics). The screen utilizes DNA repair deﬁcient Ercc1−/−
primary murine embryonic ﬁbroblasts (MEFs), which senesce
rapidly when grown at atmospheric oxygen, and detection of
senescence-associated β-galactosidase (SA-β-gal) using C12FDG
with an IN Cell Analyzer 6000. Using this platform to screen a
library of autophagy regulators, a process known to inﬂuence the
senescence phenotype of different cell types36, 37, we identiﬁed
HSP90 inhibitors as a novel class of senolytic agents, able to
induce apoptosis of senescent cells speciﬁcally. To validate
the platform, HSP90 inhibitors were tested for senolytic activity
in human cells in culture and in a progeroid mouse model
of accelerated aging, where the intervention delayed multiple
age-related co-morbidities. These results demonstrate the
utility of the screening platform for identifying novel classes of
senotherapeutics. Furthermore, the results demonstrate that
an HSP90 inhibitor used clinically is senolytic and could be
potentially repurposed to extend healthspan.
Results
Development of a screen to identify senotherapeutics. In mice
and humans, reduced expression of the DNA repair endonuclease
ERCC1-XPF, which is required for the repair of bulky DNA
lesions, interstrand crosslinks and some double-strand breaks,
causes accelerated aging38. Primary MEFs from Ercc1−/− mice
undergo premature senescence if grown at atmospheric oxygen38,
presumably as a consequence of unrepaired DNA damage.
Thus, we reasoned that these murine cells would be useful
for identifying senotherapeutic drugs that modulate senescence
driven by physiologically relevant processes that can affect all cell
types. MEFs isolated from pregnant females 13 days post-coitus
were incubated at 3% O2 followed by a shift to 20% O2 for three
passages to induce senescence (Fig. 1a). To quantify senescence,
SA-ß-Gal activity was measured using the colorimetric substrate
X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) and the
ﬂuorescent substrate C12FDG (5-dodecanoylaminoﬂuorescein-di-
b-D-galactopyranoside)39. X-gal-positive cells were counted using
a light microscope (Fig. 1b), whereas C12FDG-positive cells were
quantiﬁed via ﬂow analysis (Fig. 1c) and with an IN Cell Analyzer
6000 confocal imager (Fig. 1d). Passaging of the Ercc1-deﬁcient
MEFs at 20% O2 resulted in ~50% of the cells being senescent (S)
at passage 5 (p5), as determined by using three different methods
for measuring SA-ß-Gal (Fig. 1e). In addition, we demonstrated
that different ratios of co-plated senescent and non-senescent
cells could be measured accurately (Supplementary Fig. 1). Cell
senescence also was conﬁrmed by measuring other markers of
senescence including decreased proliferation (Fig. 2a), increased
expression of the cell cycle inhibitors p21Cip1 and p16Ink4a
(Fig. 2b, c), increased expression of the DNA damage marker
γ-H2AX (Fig. 2d) increased cell size and volume (Fig. 2e, f), and
increased percent of cells positive for expression of p16Ink4a
(Fig. 2h) and the SASP factor IL-6 (Fig. 2h) by ﬂuorescence in situ
hybridization (FISH). Together, these results demonstrate a
robust increase in the fraction of senescent Ercc1-deﬁcient MEFs
by passage 5 at 20% O2 (Supplementary Table 1).
Since detection of senescence using the IN Cell Analyzer 6000
was consistent with other methods (Supplementary Table 1) and
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offered a semi-automated approach, we used it for further drug
screening. Since ~50% of the Ercc1−/−MEFs were senescent under
our conditions, drugs that affect only senescent cells without
affecting non-senescent neighborhood cells can be identiﬁed
(Fig. 3a). Detectable outcomes for this screen include toxicity
to all cells, non-senescent cells only or senescent cells only.
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Fig. 2 Detection of senescence markers in Ercc1−/− MEFs. a Cell proliferation was measured in congenic WT and Ercc1−/− MEFs from p2 through p5. n= 2.
b Relative expression of p21Cip1 and c p16INK4a in p2 non-senescent (NS) and p5 senescent (S) Ercc1−/− MEFs determined by qRT-PCR. Error bars indicate
SD for n= 3. *p< 0.05, two-tailed Student’s t-test. d Protein expression levels of γH2AX in p2 NS and p5 S Ercc1−/− MEFs. Changes in diameter e and
volume f in p2 NS and p5 S Ercc1−/− MEFs. Error bars indicate SD for n=3. * p< 0.05, two-tailed Student’s t-test. Ratio of cells expressing p16INK4a g and IL-
6 h in p2 NS and p5 S cultures determined by ViewRNA ﬂuorescence in situ hybridization. Error bars indicate SD for n⩾=2. * p< 0.05, two-tailed Student’s
t-test. i Representative FISH image of p16INK4a and IL-6 of passage 5 S Ercc1−/− MEFs
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Fig. 1 Development of a novel assay to screen for senotherapeutics. a Schematic diagram of the assay. Passage 2 primary mouse embryonic ﬁbroblasts
MEFs from DNA repair-deﬁcient Ercc1−/− mice are passaged at 20% O2 to induce oxidative DNA damage. After 3 passages, 50% of the cells are senescent
(red) and 50% remain non-senescent (yellow). Drugs are tested on these mixed cultures to determine if they affect senescent (C12FDG positive) or
non-senescent (C12FDG negative) cells. b Representative images derived from three replicate experiments of p5 Ercc1−/− MEF cultures measuring
senescence-associated b-gal (SA-β-Gal) activity using colorimetric X-gal staining. Scale bar, 50 μm. c Representative ﬂow cytometric histogram detecting
SA-β-Gal activity using C12FDG in senescent and non-senescent Ercc1−/− MEF populations. The dotted line indicates the cut-off in intensity levels used to
deﬁne senescent cells. d Representative image from IN Cell Analyzer 6000 to detect SA-β-Gal in p5 Ercc1−/− MEFs using C12FDG. Senescent cells are
outlined in red (S), non-senescent cells are outlined in yellow (NS) and blue ﬂuorescence indicates Hoechst-stained DNA in nuclei (N) used to obtain a total
cell count. Scale bar, 50 μm. e Quantiﬁcation of the senescent cell population in non-senescent (NS) and senescent (S) p5 Ercc1−/− MEF cell cultures
detected with X-gal and with C12FDG by ﬂow cytometry and INCell 6000 analyzer. Error bars indicate SD for n= 3. *p< 0.05, two-tailed Student’s t-test
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A reduction in the ratio of senescent to non-senescent cells could
be achieved by three drug activities: (1) speciﬁcally killing
senescent cells, termed senolytics29, (2) suppressing cell senes-
cence phenotypes, termed senomorphics, or (3) increasing
proliferation of the non-senescent cells. Drugs that only increase
proliferation are not considered senotherapeutic. The percentage
of senescent MEFs relative to the total cell number was calculated
for cultures treated with drugs relative to untreated controls.
To validate the assay, we used select compounds previously
tested by the NIA-sponsored Interventions Testing Program
(ITP) for their effect on lifespan of mice. Two drugs that
extend the lifespan of mice, rapamycin and NDGA8, 9,
signiﬁcantly reduced senescence of Ercc1−/− MEFs (Fig. 3b).
Curcumin, an active ingredient of turmeric, and resveratrol,
a sirtuin agonist, neither of which extend the lifespan of mice40,
had no effect on senescent cells (Fig. 3b). In contrast, two
established senolytics, a combination of dasatinib plus quercetin
(D/Q) and navitoclax29, 32, signiﬁcantly reduced senescent and
total cell counts relative to untreated cultures. Of note, rapamycin
and NDGA reduced the number of senescent cells, but not
the total number of cells, suggesting they are senomorphic
compounds. In contrast, D/Q and navitoclax reduced both the
number of senescent cells and the total number of cells, consistent
with senolytic activity. These data demonstrate that the assay can
be used to identify senolytics and senomorphics regardless of
their molecular target.
Other aspects of the assay were validated, including measuring
the consistency of inducing cell senescence with atmospheric
oxygen, repeatability and reproducibility as well as Z′-factors for
the controls (rapamycin and non-senescent wild-type MEFs)
(Table 1). Given that rapamycin had a favorable Z′ score of >0.5
when 50% of cells were senescent, similar cell growth and passage
conditions were then used for all subsequent experiments with
rapamycin used as a positive control in every screen. These data
demonstrate that the assay has characteristics amenable to
transferable and reproducible drug discovery.
Screening a library of small molecule autophagy regulators.
Rapamycin, which regulates mTOR activity and autophagy,
attenuates expression of SASP factors and extends healthspan
in vivo9, 41, 42. Therefore, initially we screened the Enzo
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Screen-well Autophagy library containing 97 drugs in 35 different
functional classes with deﬁned autophagy-inducing or autophagy-
inhibitory activity (Fig. 4a and Supplementary Table 2). The
primary screen was performed at 1 μM concentration. Most of the
drugs had no effect on cellular senescence (Fig. 4b, grey dots), but
15 compounds signiﬁcantly reduced the fraction of senescent cells
to below 50% (Fig. 4b, blue shaded area). These 15 drugs are in 11
different functional classes (Fig. 4c) and all have been reported to
induce autophagy (Supplementary Table 2). Seven of these drugs,
including rapamycin and its homologs, did not signiﬁcantly
change the total cell number and were therefore considered
senomorphic (Fig. 4b, blue dots), whereas six drugs signiﬁcantly
reduced senescent cells and total cell number and were therefore
considered to have senolytic potential (Fig. 4b, red dots).
Table 1 Bioassay qualiﬁcation parameter
Cell senescence Repeatabilitya Reproducibilityb HTS parameter
Accuracy + std.dev Relative cell senescence Intra-assay CV (%) Inter-assay CV (%) Z′-factorc (rel. senescence)
Senescent Ercc1−/− 50.4% + 7.5% 100% 4% 15%
+Rapamycin 46% 27% 16% 0.64
Non-senescent WT 33% 13% 44% 0.34
aIntra-assay coefﬁcient of variations (CV) for deviations within the same assay
bInter-assay coefﬁcient of variations (CV) for deviations within assays performed on different days and/or by different operators
cStatistical factor for assay quality in HTS settings: rapamycin and non-senescent WT cells (passage 2) compared to senescent Ercc1−/− MEF cells (passage 5) are listed
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Also, due to the fact that lysosomal lumen alkalizers like
chloroquine could give false-positive results, we excluded
drugs known to change the lysosomal pH from our analyses43
(Supplementary Table 2). Staurosporine and Verapamil were
highly toxic to all cells and therefore excluded from further
analyses (Fig. 4b). To validate the results of the primary screen,
all 13 of the potential senotherapeutic drugs were tested again in
triplicate at 1 μM (Fig. 4d). All drugs signiﬁcantly reduced
senescence (potential senotherapeutics), but only six drugs also
signiﬁcantly reduced the total cell number (potential senolytics).
However, we cannot rule out that some of these drugs might have
toxicity on both non-senescent and senescent cells.
HSP90 inhibitors as a novel class of senolytics. To examine the
selectivity of the compounds, conﬂuent, non-senescent wild-type
MEFs and senescent Ercc1−/− MEFs were treated with four dif-
ferent concentrations of each drug for 48 h and their viability
measured using a CellTox Green assay. All but two drugs had
the same or higher toxicity to non-senescent cells at the
concentrations used (Fig. 5a,b). Plotting the viability of conﬂuent,
non-senescent cells vs. senescent cells after drug treatment
clearly shows that only two drugs, geldanamycin and 17-AAG
(tanespimycin), were able to reduce the viability of senescent cells
speciﬁcally at a concentration of 1 μM without signiﬁcantly
affecting the viability of healthy cells (Fig. 5c). Both of these drugs
are N-terminal ansamycin-derived heat shock protein (HSP90)
inhibitors44. HSP90 is a ubiquitously expressed molecular
chaperone, which plays an important role in protein stabilization
and degradation45. It is upregulated in many cancers, stabilizing
otherwise unstable oncogenic drivers such as mutant EGFR46,
mutant BRAF47, 48, wild-type and mutant HER2, as well as
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depicting drugs that speciﬁcally kill senescent cells. Plotted is the viability of non-senescent WT vs. senescent Ercc1−/− cells after treatment with each drug
for 48 h at a 1 μM concentration. Cell toxicity was deﬁned as cell viability< 75%. Only cells that kill senescent cells, without signiﬁcant toxicity to
quiescent, non-senescent cells, are considered as senolytics (indicated in yellow shaded area). d Dose response analysis of senolytic activity of 17-DMAG.
Increasing concentrations of 17-DMAG (0.1–1000 nM) were tested and plotted against the fraction of remaining senescent (red) and non-senescent cells
(yellow) after 48 h treatment. The EC50 values of their senolytic potential were determined from their dose response curves using a 4-parameter curve ﬁt
analysis (graphpad). Error bars indicate SD for n= 3. e Flow cytometric analysis of cell death of senescent Ercc1−/− MEF cell cultures treated with 17-DMAG
via AnnexinV/7-AAD staining. MEF cells are either senescent (C12FDG+; Top) or non-senescent (C12FDG−, Bottom). Live cells were double negative for
7-AAD and AnnexinV (bottom left quadrant), early apoptotic cells were positive for Annexin V (bottom right quadrant), late apoptotic cells were positive for
AnnexinV and 7-AAD (top left quadrant) and dead cells were positive for 7-AAD only (bottom right quadrant). f Quantiﬁcation of the ﬂow cytometry data.
Apoptosis of senescent (red) and non-senescent (yellow) cells was calculated by summing up all AnnexinV-positive cells. Error bars indicate SD for n= 3,
*p< 0.05, two-tailed Student’s t-test
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certain anti-apoptotic factors49. In addition to geldanamycin,
a benzoquinone ansamycin antibiotic original discovered in the
bacterium Streptomyces hygroscopicus, and its ﬁrst synthetic
derivate 17 AAD, an improved, more water soluble
geldanamycin-derived HSP90 inhibitor 17-DMAG (alvespimy-
cin) also has been tested in clinical trials50. We used 17-DMAG
for all subsequent studies as it showed a very promising proﬁle
with an almost 10-fold lower EC50 values on senescent cells
compared to overall cell death (Fig. 5d).
To determine whether HSP90 inhibition preferentially triggers
apoptosis of senescent cells, cultures of senescent Ercc1−/− MEFs
grown at 20% O2 were stained for AnnexinV/7-AAD and
C12FDG, and analyzed by ﬂow cytometry (Fig. 5e, Supplementary
Fig. 2). Using a combination of AnnexinV, an early apoptosis
phosphatidylserine binding compound, and 7-aminoactinomycin
D (7-AAD), a membrane impermeable dye that is generally
excluded from viable cells, together with C12FDG enables the
detection of cells in different stages of cell death as well as
senescence51. Treating the cells with low concentrations (50–200
nM) of 17-DMAG (17D) caused a dose-dependent, increase in
C12FDG and AnnexinV double-positive cells compared to
untreated cells. In contrast, there was no signiﬁcant increase in
apoptosis of C12FDG-negative cells, supporting the conclusion
that 17-DMAG selectively kills senescent cells (Fig. 5f).
HSP90 inhibitors are senolytic in different cell types and species.
To demonstrate that this senolytic activity of 17-DMAG was not
due to an off-target effect, seven HSP90 inhibitors from diverse
classes, including ansamycin, resorcinol, and purine and
pyrimidine-like N-terminal HSP90 inhibitors, were tested in the
assay. All of the inhibitors showed a dose-dependent reduction of
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senescent, C12FDG+MEFs (Fig. 6a) followed by a signiﬁcantly
delayed reduction in the number of passage 5, ERCC1-deﬁcient,
non-senescent MEFs (Fig. 6b). Similar to 17-DMAG, EC50 values
for the senolytic activity of the inhibitors exceeded their non-
senescent cell killing potential and corresponded well with their
previously determined IC50 values for HSP90 inhibition (Fig. 6c).
The one exception was NVP-BEP800, the only pyrimidine-like
inhibitor tested, which had an EC50 10-fold higher than its IC50,
possibly due to its intracellular concentration or localization and
did not kill non-senescent cells at all at the concentrations used.
These results support the conclusion that HSP90 is a valid
molecular target for killing senescent cells.
To determine whether the senolytic effect of the HSP90
inhibitors is cell-type or species speciﬁc, we tested 17-DMAG on
senescent cultures of primary murine mesenchymal stem cells
(MSCs) isolated from Ercc1-deﬁcient mice, human IMR90
ﬁbroblasts, and human WI38 cells (Fig. 6d). 17-DMAG
signiﬁcantly reduced the fraction of senescent human ﬁbroblasts
and mouse stem cells. Senescence was induced by oxidative stress
in murine cells, genotoxic stress in IMR90 (etoposide), and
telomere shortening in WI38. A second HSP90 inhibitor,
ganetespib, had senolytic activity in human umbilical vein
endothelial cells (HUVECs) induced to senesce with ionizing
radiation (Fig. 6e), but not in pre-adipocytes (Supplementary
Fig. 3) indicating that although very potent, not all HSP90
inhibitors work on all cell types33. These data demonstrate that
HSP90 inhibitors have senolytic activity in ﬁve cell types from two
species when senescence is caused by a variety of mechanisms.
Reduction of other senescence markers by HSP90 inhibitors.
To conﬁrm the results obtained by measuring SA-ß-Gal activity,
we incubated senescent Ercc1−/− MEF cells grown at 20% O2 with
100 nM 17-DMAG, then examined their cell size (Fig. 7a),
measured expression of p16Ink4a and the SASP factor IL-6 via
qPCR (Fig. 7b) and ﬂuorescent in situ hybridization (Fig. 7c–d)
and collected cell lysates at 6 or 24 h post-treatment to measure
γH2AX by immunoblot. All of these markers of senescence were
reduced by treatment with 17-DMAG.
HSP90 inhibitors downregulate the anti-apoptotic PI3K/AKT
pathway. Senescent cells, like cancer cells, have upregulated pro-
survival and anti-apoptotic signaling that confers resistance to
apoptotic signals29, 52. Numerous studies on tumor cells
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demonstrate that cell survival can be mediated by an HSP90-
dependent stabilization of factors such as AKT or ERK53. These
suppress apoptosis via impacting mTOR, NF-κB, FOXO3A, and
other signaling pathways (Fig. 8a). Inhibition of HSP90 leads to a
destabilization of AKT and ERK and increased apoptosis, making
HSP90 inhibitors useful for cancer treatment either alone or in
combination with other cytotoxic or cytostatic compounds such
as borzetomib, rapamycin, or tyrosine kinase inhibitors54–56.
AKT and its activated form p-AKT (Ser473) were upregulated in
late passage, senescent Ercc1-deﬁcient MEFs compared to early
passage proliferating cells (Fig. 8b). A low concentration of the
HSP90 inhibitor 17-DMAG (100 nM) was sufﬁcient to reduce the
level of p-AKT in senescent Ercc1−/− cells by 6 h and the reduc-
tion lasted for at least 24 h (Fig. 8c). In contrast, the expression of
total AKT was not altered by 17-DMAG. These results demon-
strate that HSP90 inhibitors are functional in senescent cells to
block the stabilization of p-AKT, consistent with a model in
which p-AKT plays a role inducing cell senescence57. Disruption
of the HSP90-AKT interaction leads to a destabilization of the
active, phosphorylated form of AKT, resulting in apoptosis of
senescent cells.
HSP90 inhibitor delays the onset of several age-related
symptoms in Ercc1−/Δ mice. To examine the effects of HSP90
inhibitors on the healthspan of aged mice, the Ercc1−/Δ mouse
model of a human progeroid syndrome was used. The mice
spontaneously develop age-related degenerative diseases and have
a maximum lifespan of 7 months58. 17-DMAG was administered
three times per week every 3 weeks at a relatively high con-
centration (10 mg/kg) to Ercc1−/Δ mice beginning at 6 weeks of
age (Fig. 9a). Phenotypes associated with aging were measured
three times per week by an investigator blinded as to treatment
groups29. Treatment with 17-DMAG resulted in a signiﬁcant
reduction in a composite score of age-related symptoms including
kyphosis, dystonia, tremor, loss of forelimb grip strength, coat
condition, ataxia, gait disorder, and overall body condition, as
shown in detail for a sex-matched and age-matched sibling mouse
pair (Fig. 9b) and all the treated mice (Fig. 9c, Supplementary
Fig. 4). The signiﬁcant therapeutic effect of 17-DMAG on
healthspan by intermittent treatment was conﬁrmed in a second,
short term treatment cohort (Supplementary Fig. 5).
To determine if the delay of age-related diseases in HSP90
inhibitor treated mice is due to its senolytic effect, Ercc1−/Δ mice
were treated three times over a 1 week period with 10 mg/kg of
17-DMAG and sacriﬁced 4 days after the last treatment. qPCR
analyses showed a signiﬁcant reduction of p16INK4A expression in
the kidneys of treated mice compared to vehicle treated mice
(Fig. 9d), but no signiﬁcant changes in the liver (Fig. 9e). Taken
together, these data demonstrate that periodic treatment with
senolytic HSP90 inhibitors is sufﬁcient to reduce senescent cell
markers in vivo and delay the onset of age-related phenotypes,
indicating a health span extension. These results also demonstrate
that senolytic compounds identiﬁed in the senescent MEF assay
indeed can reduce the level of senescent markers in vivo and
extend healthspan in a mouse model of accelerated aging,
validating the screening platform.
Discussion
Cellular senescence, driven by different types of stress including
genotoxic, oxidative, and inﬂammatory, has been demonstrated
to be a key mediator of aging14, 37. Interestingly, the clearance of
senescent cells from genetically engineered mice with accelerated
or normal aging or by treatment with senolytic compounds
targeting pro-survival pathways, extends healthspan20, 26, 29, 35.
These results strongly suggest that optimizing approaches to
reduce senescence or eliminate senescent cells could have a sig-
niﬁcant impact on human healthspan. However, an approach to
identify novel senotherapeutic agents and more optimal drug
combinations is needed. Thus, we developed a screening platform
for identifying and testing senotherapeutic agents, including
compounds that kill senescent cells speciﬁcally (senolytics) or
suppress senescent phenotypes (senomorphics), using primary
murine embryonic ﬁbroblasts. Given that one of the major drivers
of cell senescence is DNA damage, we utilized MEFs deﬁcient
in the ERCC1-XPF endonuclease critical for nucleotide
excision repair, interstrand crosslink repair, and repair of some
double-strand breaks59. Cultivation of the primary, passage
2 Ercc1-deﬁcient MEFs at 20% O2 for three passages results in
senescence in ~50% of the MEFs, conﬁrmed by quantitating
several senescence markers including SA-β-Gal activity using the
ﬂuorescent substrate C12FDG as well as p16INK4a, p21Cip1,
and IL-6 expression, cell shape and volume and γH2AX.
Thus, it is possible to assess the effect of drugs on senescent
(C12FDG-positive) and non-senescent (C12FDG-negative) cells
on the same plate.
We validated the screening platform using compounds pre-
viously tested by the National Institute on Aging ITP. Rapamycin
and NDGA, two compounds able to extend lifespan in naturally
aged mice8, 9, act as senomorphics, reducing the fraction of
senescent cells without affecting cell viability (Fig. 1). In contrast,
dasatinib plus quercetin, identiﬁed as senolytics through a
bioinformatics approach29, and navitoclax32, 33 proved senolytic
in our assay, killing speciﬁcally senescent cells. Given that rapa-
mycin is a known regulator of autophagy, we initially used the
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platform to screen a small molecule library of autophagy reg-
ulators for senotherapeutic activity. Here, 97 drugs in different
functional classes were tested, including inhibitors of mTOR and
mTOR complexes 1 and 2 and serine, threonine, and tyrosine
kinases, proteasome inhibitors, ER stress inhibitors, and inhibi-
tors of heat shock proteins. Fifteen percent of the compounds,
all of which are autophagy inducers, had apparent senolytic or
senomorphic activity (Fig. 4). These compounds included the
mTOR inhibitors rapamycin, NVP-BEZ235, and timosaponin
AIII60. The two Ca2+ channel blockers, loperamide and niguldi-
pine, and the dopamine antagonist ﬂuspirilene also had a seno-
morphic effect on primary MEFs. Interestingly, in a recent screen
of a subset of FDA-approved compounds, several dopamine as
well as serotonin antagonists had senomorphic activity in this
MEF assay (unpublished data). It is important to note that
identifying autophagy regulators that have no effect on senes-
cence is also of interest, since this suggests that only a subset of
mechanisms by which autophagy is regulated are important for
modulating senescence.
In addition to senomorphic drugs, two senolytic compounds
were detected in the screen, geldanamycin and 17-AAG, both of
which are HSP90 inhibitors61. HSP90 and its homologs are
essential proteins that interact with co-chaperones to ensure the
correct folding, stabilization or, if necessary, degradation of client
proteins involved in diverse cellular processes, ranging from
development and cell growth to apoptosis and cancer50. Given
that HSP90s are expressed in the cytosol (HSP90 a and b), ER
(Grp94), mitochondria (TRAP1), and, under some conditions, in
the nucleus, or can be secreted, they represent excellent ther-
apeutic targets to inﬂuence a variety of cellular processes,
including cell survival62–64. The importance of HSP90 in con-
ferring cell survival has been demonstrated in the cancer ﬁeld,
with more than a dozen HSP90 inhibitors tested clinically as
chemotherapeutics, either alone or as drug-sensitizers in combi-
nation with other drugs or irradiation.
We conﬁrmed that the effects of geldanamycin and 17-AAG
are speciﬁc to HSP90 by testing 4 different classes of N-terminal,
ATP-competitive HSP90 inhibitors (Fig. 6). All of these inhibitors
have a dose-dependent senolytic effect on senescent MEFs at nM
concentrations. We demonstrated that the senolytic effect of the
HSP90 inhibitors is not cell type-speciﬁc or species-speciﬁc using
senescent MEF and mesenchymal stem cells, and human lung
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ﬁbroblasts (IMR90 and WI-38) and vascular endothelial cells
(HUVECs). Furthermore, HSP90 inhibitors have senolytic
activity on cells induced to undergo senescence in different ways:
oxidative stress, genotoxic stress, and replicative stress. We also
demonstrated that other markers of cell senescence including cell
size, cell cycle regulators like p16Ink4A, SASP factors like IL-6, and
the DNA damage marker γH2AX was signiﬁcantly reduced after
HSP90 inhibitor treatment (Fig. 7).
Senescent cells, like cancer cells, are known to employ anti-
apoptotic and pro-survival pathways, which can at least in part
be attributed to HSP90 and its stabilizing effect on its client
proteins57, 65. The HSP90 client proteins AKT and p-AKT (S473),
key regulators of the anti-apoptotic PI3K/AKT pathway, are
upregulated in senescent MEFs (Fig. 8). In several types of cancer
cells, AKT suppresses apoptosis induced by chemotherapeutics,
oxidative and osmotic stress, and irradiation66, 67. Treating
senescent MEFs with HSP90 inhibitors results in an almost
complete abrogation of the active, phosphorylated AKT form
after only 6 h of treatment, with effects lasting for at least 24 h
(Fig. 8). Downregulation of this survival pathway may contribute
to the senolytic activity of HSP90 inhibitors. Similar results were
obtained when we used the senescent MEF assay to conﬁrm the
senolytic activities of quercetin, a plant ﬂavonoid, and navitoclax,
both of which target survival pathways29. Navitoclax inhibits
Bcl2, Bcl-w, and Bcl-XL, which are all known to be regulated
by AKT68. Also, quercetin has been reported to affect levels of
certain Bcl-2 family members and to inhibit AKT activity.
Importantly, repeated intermittent courses of treatment with
the HSP90 inhibitor 17-DMAG signiﬁcantly delayed onset of
multiple age-related symptoms in progeroid mice, leading to an
overall healthspan improvement (Fig. 9, Supplementary Fig. 5).
Acute treatment of mice resulted in more than 50% reduction in
expression of p16INK4a in the kidney, suggesting that 17-DMAG
had senolytic activity in vivo. These in vivo results are consistent
with previous results using the combination of dasatinib and
quercetin, which also improved healthspan in Ercc1−/Δ mice29.
Furthermore, these results are consistent with the reported effect
of 17-DMAG in improving nephropathy and atherosclerosis in
diabetic mice69. Taken together, these results indicate that our
in vitro screen can successfully identify candidates that are
effective for alleviating dysfunction in vivo.
Although the HSP90 inhibitors have senolytic activity in
culture and in vivo, it is likely that HSP90 inhibitors will be more
effective in combination with other FDA-approved drugs that
target other anti-apoptotic pathways in senescent cells. Indeed,
our preliminary results using the screening platform suggests that
it may be possible to identify more effective senolytic drug
combinations, including combinations of other drugs with HSP90
inhibitors, which could be used to extend healthspan in humans.
Senolytic drugs also might prove useful in delaying, preventing,
or treating age-related chronic diseases as well as other diseases
and conditions related to increased senescent cell burden, such as
idiopathic pulmonary ﬁbrosis, obesity with metabolic syndrome,
osteoarthritis, and cancer survivors treated with irradiation or
chemotherapy2, 70–72.
Methods
Chemicals and materials. DMEM (Corning, Corning, NY, cat# 10-013-CV),
Ham’s F10 (Gibco, cat#12390-035), fetal bovine serum (Tissue Culture Biologics,
Tulare, Ca, cat# 101), 1× non-essential amino acids (Corning, Corning, NY, cat#
25-025-Cl), MycoAlert PLUS mycoplasma detection kit (Lonza, cat# LT07-710),
baﬁlomycin A1 (Sigma, cat# B1793), paraformaldehyde (Sigma-Aldrich, St. Louis,
MO, cat# 47698), glutaraldehyde (Sigma-Aldrich, St. Louis, MO, cat# G7651),
5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside (X-gal, Invitrogen, Eugene,
CA, cat# B1690), C12FDG (Setareh Biotech, cat# 7188), Hoechst 33342 (Life
Technologies, Carlsbad, CA, cat# H1399), PE-Annexin V Apoptosis Detection Kit I
(BD Pharmingen, cat# 559763), rapamycin (Fisher Scientiﬁc, cat# 50488990),
NDGA (Sigma, St. Louis, MO, cat# 74540), curcumin (Sigma, St. Louis, MO, cat#
C7727), dasatinib (LC Laboratories, Woburn, MA, cat# D-3307), quercetin (Sigma,
St. Louis, MO, cat# 1592409), Navitoclax (VWR, West Chester, PA, cat# 101756-
198), Screen-Well Autophagy Library (Enzo Life Sciences, Inc., cat# BML-2837),
17-DMAG (Selleck Chemical LLC, cat# 508439), ganetespib (Selleck Chemical,
cat# S1159), NVP-AUY922 (ChemScene, Monmouth Junction, NJ, cat# CS-0136),
BIIB021 (Chemscene, Monmouth Junction, NJ, cat# CS-0168), PU-H71
(Chemscene, Monmouth Junction, NJ, cat# CS-0546), NVP-BEB800 (Selleck
Chemical LLC, cat# S1498), AT13387 (Selleck Chemical LLC, cat# S1163), eto-
poside (Cayman Chemical Co, Ann Arbor, MI, cat# 12092), View ISH Cell Assay
Kit 24 assays, Alexa LPs (Afﬁmetryx, Santa Clara, CA, cat# QVC0001), BD LSR2
cytometer (Becton Dickinson), FlowJo analysis software (Tree Star Inc.), IN Cell
Analyzer 6000 Cell Imaging System (GE Healthcare, Pittsburgh).
MEF isolation. The Ercc1−/− MEFs were isolated from pregnant females at
embryonic day 13 (E13) and cultured in a 1:1 mixture of Dulbecco’s modiﬁed
Eagle’s medium and Ham’s F10 with 10% fetal bovine serum, 1× nonessential
amino acids, penicillin, and streptomycin and incubated at 3% O2 initially, followed
by a shift to 20% for 5 passages to induce senescence73. Animal use was approved
by the Scripps Florida Institutional Animal Care and Use Committee (protocol
12-027 and 12-016). Cells were gentoyped by Transnetyx (Cordova, TN, USA) and
routinely tested for mycoplasma contamination using the MycoAlert PLUS
mycoplasma detection kit.
Drug preparation. All drugs were either prepared (HSP90 inhibitors) or provided
(compounds within the autophagy library) as 10 mM stock solutions in DMSO.
They were then diluted in culture medium to obtain a suitable working solution.
As a negative control, culture medium with DMSO at the same concentration was
used. Once resuspended, the stock solutions were aliquoted and stored at −20 °C.
Assay to identify senotherapeutics. MEFs (5 × 103) at passage 5 at 20% O2 were
seeded per well in 96-well plates at least 6 h prior to treatment. Following addition
of the drugs, the MEFs were incubated for 24 to 48 h under 20% O2 oxygen
conditions. For ﬂuorescence analysis of SA-β-Gal activity, cells were washed 1×
with PBS, C12FDG (10 µM) was added to the culture medium, and the cells were
incubated for 1.5–2 h39. Ten minutes prior to analysis, the DNA intercalating
Hoechst dye (2 µg/ml) was added to the cells. For quantitative analysis of cell
number (Hoechst staining) and number of C12FDG positive, senescent cells, a
laser-based line scanning confocal imager IN Cell Analyzer 6000 with large ﬁeld-of
view sCMOS camera detection technology was used. An acquisition protocol was
established using Acquisition software v4.5, including parameters such as the plates
and wells that were imaged, wavelengths, and exposure time. The acquired images
were analyzed using the Multi Target Analysis Module that allows the creation of
various decision trees and the application of appropriate classiﬁcation ﬁlters to
different image stacks. All samples were analyzed in duplicate with 3-5 ﬁelds per
well and mean values and standard deviations being calculated accordingly.
Assay validation parameters. For all samples intra-assay and inter-assay
coefﬁcient of variations were calculated. In addition, the Z′ value for the assay was
calculated using senescent Ercc1−/− cells as negative and non-senescent wild-type
cells as positive controls, although for technical reasons wild-type cells were not
used as positive controls in high content screens. Rapamycin was used as positive
control, a drug we have demonstrated as reducing senescence, and Z′ values with
these controls were calculated according to Zhang et al.74.
Colorimetric senescence-associated β-galactosidase (SA-β-Gal) activity.
Colorimetric SA-β-Gal activity was measured as previously described by Zhao J
et al.51. In brief, MEF cells were washed 3× with PBS and then ﬁxed with 2%
formaldehyde and 0.2% glutaraldehyde in PBS for 10 min. Following ﬁxation,
cells were incubated in SA-β-Gal staining solution (1 mg/ml 5-bromo-4-chloro-3-
indolyl-beta-d-galactopyranoside (X-gal), 1×citric acid/sodium phosphate buffer
(pH 6.0), 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 150 mM
NaCl, and 2 mM MgCl2) at 37 °C for 16–18 h. The enzymatic reaction was stopped
by washing the cells three times with ice-cold PBS. Cells were counterstained with
Hoechst solution and analyzed with a ﬂuorescence microscope.
Flow cytometry. For ﬂow analysis, senescent MEF cells from passage 5 were
seeded at 70–80% conﬂuence in 6-well culture plates and cultured for 24 h at 37 °C,
20% O2. For MEF, 5 × 105 cells/well were used. Following addition of the drugs, the
MEFs were incubated for 12–24 h under 20% O2 oxygen conditions. Lysosomal
alkalinization was induced by pretreating cells with 100 nM baﬁlomycin A1 for 1 h
in fresh cell culture medium at 37 °C and 20% O2. C12FDG (10 μM) solution
was then added to the cell culture medium for 2 h. The cells were harvested by
trypsinization and resuspended in 1× Annexin V buffer containing 5 µl of PE
Annexin V-PE and 5 µl 7-AAD per 1 × 105 cells/100 µl. The cells were analyzed by
ﬂow cytometry within 1 h. To estimate relative SA-β-Gal activity, a two-parameter
display of FSC vs. SSC was set up excluding subcellular debris. The events within
this region were depicted in a green ﬂuorescence histogram where the Y axis
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indicates cell number and the X axis indicates C12FDG ﬂuorescence intensity in log
scale. On this histogram, the relative SA-β-Gal activity of a given sample was
compared with positive or negative control cells using the MFI of the population.
Non-labeled samples were used to determine auto-ﬂuorescence. To estimate the
percentage of C12FDG-positive cells, an appropriate negative control was used as a
reference (e.g., early passage non-stressed cells) and the ﬂuorescence histogram was
divided into two compartments by setting up a boundary between the negative
(dim ﬂuorescence) and positive cells (bright ﬂuorescence). The percentage of
positive cells was estimated by dividing the number of events within the
bright ﬂuorescence compartment by the total number of cells in the histogram.
To estimate the number of live cells in SA-β-Gal positive and negative cells the
subpopulation analyzed (C12FDG-positive cells or C12FDG-negative cells) was
depicted on a two-parameter display of PE vs. PE-Cy5. The cells that were
considered alive were those negative for PE (Annexin V-PE) and PE-Cy5 (7-AAD)
(Supplementary Fig. 8A, B).
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR).
Snap frozen tissues were preserved in RNAlater RNA stabilization solution
(ThermoFisher). Total RNA was extracted from primary MEFs or kidney using
TRIZOL reagent (Life Technologies), and 1.5 μg of RNA was subjected to the
synthesis of complementary DNA (cDNA) using SuperScript VILO cDNA
synthesis kit. qRT-PCR was performed in a StepOnePlus Real-Time PCR system
using Platinum SYBR Green qPCR SuperMix-UDG (ThermoFisher). Target
gene expression was calculated using the comparative CT method (ΔΔCT) and
normalized to an internal control gene Actb (β-actin). Primers used are as follows:
Cdkn1a (p21) forward: 5′-GTCAGGCTGGTCTGCCTCCG-3′; Cdkn1a (p21)
reverse: 5′-CGGTCCCGTGGACAGTGAGCAG-3′; Cdkn2a (p16) forward:
5′-CCCAACGCCCCGAACT-3′; Cdkn2a (p16) reverse: 5′-GCAGAAGAGCTGCT
ACGTGAA-3′; Actb (β-actin) forward: 5′-GATGTATGAAGGCTTTGGTC-3′;
Actb (β-actin) reverse: 5′-TGTGCACTTTTATTGGTCTC-3′.
QuantiGene ViewRNA FISH. RNA FISH was performed using the QuantiGene
ViewRNA protocol. Brieﬂy, cells were ﬁxed with 4% formaldehyde for 30 min at
room temperature. After ﬁxation, cells were permeabilized with detergent solution
for 5 min (Affymetrix, Santa Clara, CA) and treated with proteinase K (Affymetrix)
for 10 min. Cells were hybridized for 3 h at 40 °C with a Quantigene ViewRNA
designed probe for mouse p16Ink4a (VB1-13052-06 Cdkn2a, MOUSE—ViewRNA
TYPE 1) and mouse IL-6 (VB6-13850-06 Il6, MOUSE ViewRNA TYPE 6). After
hybridization, the signal was ampliﬁed by sequential reaction of the PreAmpliﬁer
and the Ampliﬁer mix (Affymetrix) followed by conjugation with the ﬂuorescent
dye-conjugated label probe (Affymetrix). Cells were counterstained with DAPI
(Affymetrix). Images were taken by the Olympus Fluoview FV1000 confocal
microscope.
MSC isolation. MSC were obtained from Ercc1−/Δ mouse bone marrow and
cultured in high glucose DMEM supplemented with 15% FBS, 2 mM glutamine,
100 U/ml penicillin, and 0.1 mg/ml streptomycin (all from Sigma-Aldrich, St Louis,
MO, USA). The MSCs were cultured in low oxygen conditions (3% O2) to avoid
oxidative damage. The generated MSCs displayed a CD105+, CD106+, CD73+,
Sca-1+, CD34−, CD45−, and CD31− phenotype, ﬁbroblast-like morphology, and
multi-lineage differentiation capacity. Senescence was induced by serial passage
and the cells used for drug testing were at passage 5.
IMR90 lung ﬁbroblasts. Human IMR90 lung ﬁbroblasts were obtained from
American Type Culture Collection (ATCC) and cultured in EMEM medium with
10% FBS and pen/strep antibiotics. To induce senescence, cells were treated for 24
h with 20 μM etoposide. Two days after etoposide removal, about 70% of IMR90
cells were SA-β-Gal positive. Cells were treated for 48 h with 100 nM 17-DMAG
and the percentage of SA-β-Gal-positive cells was determined using C12FDG-based
senescence assay.
WI38 cells. WI-38 fetal human diploid ﬁbroblast-like cells (Hayﬂick, 1965) were
derived from ATCC and cultured in DMEM 4.5 g/l glucose with 10 % FBS and
pen/strep antibiotics. Replicative senescence with a reduced proliferation rate of
10% was induced by cultivating the cells for 110 d (41 population doublings).
Senescent cells were treated with 100 nM 17-DMAG for 24 h and the percentage of
SA-β-Gal-positive cells determined as described.
HUVECs and pre-adipocytes. HUVECs were purchased from Lonza and grown in
Clonetics endothelial cell growth medium-2 (Lonza, Walkersville, MD) according
to the protocol provided by the company. Primary human pre-adipocytes were
isolated from healthy, lean kidney transplant donors. The protocol was approved
by the Mayo Clinic Foundation Institutional Review Board for Human Research.
Fat tissue was digested by collagenase, ﬁltered, centrifuged, and treated with an
erythrocyte lysis buffer. Cells were subcultured 5–7 times before study75. HUVECs
and pre-adipocytes were radiated in a RS2000 X-Ray Irradiator (RAD
Source Technologies) at 10 Gy to induce senescence or were sham-irradiated.
Pre-adipocytes were senescent by 20 days after radiation and HUVECs after
14 days, exhibiting SA‐β-Gal positivity and SASP factor expression by ELISA
(IL‐6, MCP‐1). Cell viability after treatment was measured by ATPLite Kit
(cat# 6016941, PerkinElmer, Waltham, MA). The assay was performed following
the manufacturer’s instructions. Luminescence was read using a multi scan plate
reader (Fisher, Waltham, MA). Cell death was measured with crystal violet.
Cells were washed twice with PBS and then incubated with PBS containing 1%
paraformaldehyde for 15 min at room temperature and stained with 0.1% crystal
violet for 15 min at room temperature. Cells were washed with deionized water and
staining intensity was measured with a spectrometer at λ540.
Immunoblot detection of senescent markers. A total of 20–40 µg of total
protein isolated from cell culture were loaded per lane for Western blot analysis.
Antibodies used in the study were mouse anti-γH2AX (1:200, Anti-phospho-
Histone H2A.X (Ser139) antibody, clone JBW301, Millipore, Billerica, MA),
mouse anti-HSP90 (1:1000, NBP1-60608, Novus Biologicals, Littleton, CO), mouse
anti-p-AKT (1 µg/ml, MAB2687, R&D system, Minneapolis, MN), rabbit anti-AKT
(1:500, sc-397, Santa Cruz Biotechnology, Dallas, Texas), and rabbit anti-β-Actin
(1:1000, #2764, Cell Signaling, Danvers, MA). The secondary antibodies included
anti-rabbit or anti-mouse IgG obtained from Santa Cruz, CA.
In vivo studies. All animals were bred in the animal research center at The Scripps
Research Institute, Jupiter, Florida. Ercc1−/Δ and p16Luc/+;Ercc1−/Δ mice (Ercc1−/Δ
mice provided by L.J. Niedernhofer; p16Luc/+ mice provided by C. E. Burd) were
bred in an f1 background (C57Bl/6:FVB/n). Genotyping was done on an ear punch
by Transnetyx (Cordova, TN). Genotyping of the Ercc1 allele was done by PCR
co-ampliﬁcation of the 3′-end of exon 7 from the WT allele and the neomycin
resistance marker cloned into exon 7 of the targeted allele76. Randomized Ercc1−/Δ
mice were treated with 10 mg/kg 17-DMAG formulated in PBS and administered
by oral gavage, beginning at 6 weeks of age. Litters with multiple Ercc1−/Δ mice
were used to enable comparison of sex-matched, sibling pairs treated with drug vs.
vehicle only. The sample size was estimated based on previous senolytic treatment
studies29. Treatment was 3× per week, 1 week on, followed by 2 weeks off. Animal
weights were measured weekly. There was a small but not signiﬁcant decline in
body weight in the HSP90-treated group at the end of each treatment cycle
(Supplementary Fig. 4A). Animals were scored three times per week for the onset
of progeroid symptoms including kyphosis due to osteoporosis, tremor, dystonia,
coat condition, ataxia, loss of grip strength, body condition, gait disorders, hind
limb paralysis, and urinary incontinence. The investigator recording onset and
severity of symptoms was blinded as to treatment groups. All symptoms were
scored on a scale of 0, 0.5, or 1.0, with 0 indicating no symptom. 0.5 indicates the
symptom was detected but not consistently expressed. A score of 1 indicates when
the animal begins to express the symptom 100% of the time. Dystonia is the only
symptom that was scored on a scale of 0–5 to grade its progression. Thus each
animal could have a maximum score of 12 indicating full manifestation of all
age-related symptoms29. There were 6 animals each in the treatment group (n= 4
for females, n= 2 for males) and the vehicle only group (n= 3 for males and
females) for Ercc1−/Δ mice and 4 animals (n= 2 for males and females) each in the
treatment group and vehicle only group for p16Luc/+;Ercc1−/Δ.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the paper and its Supplementary Information ﬁles, and
from the authors on request.
Received: 19 January 2017 Accepted: 21 June 2017
References
1. Munoz-Espin, D. & Serrano, M. Cellular senescence: from physiology to
pathology. Nat. Rev. Mol. Cell Biol. 15, 482–496 (2014).
2. van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446
(2014).
3. Zhu, Y., Armstrong, J. L., Tchkonia, T. & Kirkland, J. L. Cellular senescence and
the senescent secretory phenotype in age-related chronic diseases. Curr. Opin.
Clin. Nutr. Metab. Care 17, 324–328 (2014).
4. LeBrasseur, N. K., Tchkonia, T. & Kirkland, J. L. Cellular senescence and the
biology of aging, disease, and frailty. Nestle Nutr. Inst. Workshop Ser. 83, 11–18
(2015).
5. Goldman, D. P. et al. Substantial health and economic returns from delayed
aging may warrant a new focus for medical research. Health Aff. 32, 1698–1705
(2013).
6. Kirkland, J. L., Stout, M. B. & Sierra, F. Resilience in aging mice. J. Gerontol. A
Biol. Sci. Med. Sci. 71, 1407–1414 (2016).
7. Sierra, F. Moving geroscience into uncharted waters. J. Gerontol. A Biol. Sci.
Med. Sci. 71, 1385–1387 (2016).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00314-z
12 NATURE COMMUNICATIONS |8:  422 |DOI: 10.1038/s41467-017-00314-z |www.nature.com/naturecommunications
8. Harrison, D. E. et al. Acarbose, 17-alpha-estradiol, and nordihydroguaiaretic
acid extend mouse lifespan preferentially in males. Aging Cell 13, 273–282
(2014).
9. Miller, R. A. et al. Rapamycin-mediated lifespan increase in mice is dose and
sex dependent and metabolically distinct from dietary restriction. Aging Cell 13,
468–477 (2014).
10. Alfaras, I. et al. Pharmacological strategies to retard cardiovascular aging. Circ.
Res. 118, 1626–1642 (2016).
11. Newman, J. C. et al. Strategies and challenges in clinical trials targeting human
aging. J. Gerontol. A Biol. Sci. Med. Sci. 71, 1424–1434 (2016).
12. von Zglinicki, T. Role of oxidative stress in telomere length regulation and
replicative senescence. Ann. N. Y. Acad. Sci. 908, 99–110 (2000).
13. Toussaint, O., Medrano, E. E. & von Zglinicki, T. Cellular and molecular
mechanisms of stress-induced premature senescence (SIPS) of human diploid
ﬁbroblasts and melanocytes. Exp. Gerontol. 35, 927–945 (2000).
14. Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J. & Kirkland, J. L. Cellular
senescence and the senescent secretory phenotype: therapeutic opportunities.
J. Clin. Invest. 123, 966–972 (2013).
15. Childs, B. G., Durik, M., Baker, D. J. & van Deursen, J. M. Cellular senescence
in aging and age-related disease: from mechanisms to therapy. Nat. Med. 21,
1424–1435 (2015).
16. Krishnamurthy, J. et al. Ink4a/Arf expression is a biomarker of aging. J. Clin.
Invest. 114, 1299–1307 (2004).
17. Rodier, F. et al. Persistent DNA damage signalling triggers senescence-
associated inﬂammatory cytokine secretion. Nat. Cell Biol. 11, 973–979 (2009).
18. Sedelnikova, O. A. et al. Senescing human cells and ageing mice accumulate
DNA lesions with unrepairable double-strand breaks. Nat. Cell Biol. 6, 168–170
(2004).
19. Baker, D. J. et al. Clearance of p16Ink4a-positive senescent cells delays ageing-
associated disorders. Nature 479, 232–236 (2011).
20. Xu, M. et al. Targeting senescent cells enhances adipogenesis and metabolic
function in old age. Elife 4, e12997 (2015).
21. Baker, D. J. et al. Naturally occurring p16-positive cells shorten healthy lifespan.
Nature 530, 184–189 (2016).
22. Roos, C. M. et al. Chronic senolytic treatment alleviates established
vasomotordysfunction in aged or atherosclerotic mice. Aging Cell 15, 973–7
(2016).
23. Childs, B. G. et al. Senescent intimal foam cells are deleterious at all stages of
atherosclerosis. Science 354, 472–477 (2016).
24. Schafer, M. J. et al. Cellular senescence mediates ﬁbrotic pulmonary disease.
Nat. Commun. 8, 14532 (2017).
25. Jeon, O. H. et al. Local clearance of senescent cells attenuates the development
of post-traumatic osteoarthritis and creates a pro-regenerative environment.
Nat. Med. 23, 775–781 (2017).
26. Ogrodnik, M. et al. Cellular senescence drives age-dependent hepatic steatosis.
Nat. Commun. 8, 15691 (2017).
27. Palmer, A. K. et al. Cellular senescence in type 2 diabetes: a therapeutic
opportunity. Diabetes 64, 2289–2298 (2015).
28. Kirkland, J. L. & Tchkonia, T. Clinical strategies and animal models for
developing senolytic agents. Exp. Gerontol. 68, 19–25 (2015).
29. Zhu, Y. et al. The Achilles’ heel of senescent cells: from transcriptome to
senolytic drugs. Aging Cell 14, 644–58 (2015).
30. Zhu, Y. et al. New agents that target senescent cells: the ﬂavone, ﬁsetin, and the
BCL-XL inhibitors, A1331852 and A1155463. Aging 9, 955–963 (2017).
31. Wang, Y. et al. Discovery of piperlongumine as a potential novel lead for the
development of senolytic agents. Aging 8, 2915–2926 (2016).
32. Zhu, Y. et al. Identiﬁcation of a novel senolytic agent, navitoclax, targeting the
Bcl-2 family of anti-apoptotic factors. Aging Cell 15, 428–435 (2016).
33. Chang, J. et al. Clearance of senescent cells by ABT263 rejuvenates aged
hematopoietic stem cells in mice. Nat. Med. 22, 78–83 (2016).
34. Baar, M. P. et al. Targeted apoptosis of senescent cells restores tissue
homeostasis in response to chemotoxicity and aging. Cell 169, 132–147 e116
(2017).
35. Kirkland, J. L. & Tchkonia, T. Cellular senescence: a translational perspective.
EBioMedicine 21, 21–28 (2017).
36. Korolchuk, V. I., Miwa, S., Carroll, B. & von Zglinicki, T. Mitochondria in cell
senescence: Is mitophagy the weakest link? EBioMedicine 21, 7–13 (2017).
37. Jurk, D. et al. Chronic inﬂammation induces telomere dysfunction and
accelerates ageing in mice. Nat. Commun. 2, 4172 (2014).
38. Niedernhofer, L. J. et al. A new progeroid syndrome reveals that genotoxic
stress suppresses the somatotroph axis. Nature 444, 1038–1043 (2006).
39. Debacq-Chainiaux, F., Erusalimsky, J. D., Campisi, J. & Toussaint, O. Protocols
to detect senescence-associated beta-galactosidase (SA-[beta]gal) activity,
a biomarker of senescent cells in culture and in vivo. Nat. Protoc. 4, 1798–1806
(2009).
40. Strong, R. et al. Evaluation of resveratrol, green tea extract, curcumin,
oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically
heterogeneous mice. J. Gerontol. A Biol. Sci. Med. Sci. 68, 6–16 (2013).
41. Laberge, R. M. et al. MTOR regulates the pro-tumorigenic senescence-
associated secretory phenotype by promoting IL1A translation. Nat. Cell Biol.
17, 1049–1061 (2015).
42. Wang, R. et al. Rapamycin inhibits the secretory phenotype of senescent cells by
a Nrf2-independent mechanism. Aging Cell 16, 564–574 (2017).
43. Rubinsztein, D. C., Codogno, P. & Levine, B. Autophagy modulation as a
potential therapeutic target for diverse diseases. Nat. Rev. Drug Discov. 11,
709–730 (2012).
44. Biamonte, M. A. et al. Heat shock protein 90: inhibitors in clinical trials. J. Med.
Chem. 53, 3–17 (2010).
45. Taipale, M., Jarosz, D. F. & Lindquist, S. HSP90 at the hub of protein
homeostasis: emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 11,
515–528 (2010).
46. Gomez-Casal, R. et al. The HSP90 inhibitor ganetespib radiosensitizes human
lung adenocarcinoma cells. Cancers 7, 876–907 (2015).
47. da Rocha Dias, S. et al. Activated B-RAF is an Hsp90 client protein that is
targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
Cancer. Res. 65, 10686–10691 (2005).
48. Xu, W. et al. Sensitivity of epidermal growth factor receptor and ErbB2 exon
20 insertion mutants to Hsp90 inhibition. Br. J. Cancer. 97, 741–744 (2007).
49. Workman, P. & Powers, M. V. Chaperoning cell death: a critical dual role for
Hsp90 in small-cell lung cancer. Nat. Chem. Biol. 3, 455–457 (2007).
50. Trepel, J., Mollapour, M., Giaccone, G. & Neckers, L. Targeting the dynamic
HSP90 complex in cancer. Nat. Rev. Cancer. 10, 537–549 (2010).
51. Zhao, J. et al. Quantitative analysis of cellular senescence in culture and in vivo.
Curr. Protoc. Cytom. 79, 9 51 51–59 51 25 (2017).
52. Wang, E. Senescent human ﬁbroblasts resist programmed cell death, and failure
to suppress bcl2 is involved. Cancer Res. 55, 2284–2292 (1995).
53. Karkoulis, P. K., Stravopodis, D. J., Konstantakou, E. G. & Voutsinas, G. E.
Targeted inhibition of heat shock protein 90 disrupts multiple oncogenic
signaling pathways, thus inducing cell cycle arrest and programmed cell death
in human urinary bladder cancer cell lines. Cancer Cell Int. 13, 11 (2013).
54. Wright, J. J. Combination therapy of bortezomib with novel targeted agents: an
emerging treatment strategy. Clin. Cancer Res. 16, 4094–4104 (2010).
55. De Raedt, T. et al. Exploiting cancer cell vulnerabilities to develop a
combination therapy for ras-driven tumors. Cance. Cell 20, 400–413 (2011).
56. Mimnaugh, E. G. et al. Simultaneous inhibition of hsp 90 and the proteasome
promotes protein ubiquitination, causes endoplasmic reticulum-derived
cytosolic vacuolization, and enhances antitumor activity. Mol. Cancer Ther. 3,
551–566 (2004).
57. Astle, M. V. et al. AKT induces senescence in human cells via mTORC1 and
p53 in the absence of DNA damage: implications for targeting mTOR during
malignancy. Oncogene 31, 1949–1962 (2012).
58. Dolle, M. E. et al. Broad segmental progeroid changes in short-lived Ercc1
(-/Delta7) mice. Pathobiol. Aging Age Relat. Dis. 1 (2011).
59. Niedernhofer, L. J. Nucleotide excision repair deﬁcient mouse models and
neurological disease. DNA. Repair 7, 1180–1189 (2008).
60. Lamming, D. W., Ye, L., Sabatini, D. M. & Baur, J. A. Rapalogs and mTOR
inhibitors as anti-aging therapeutics. J. Clin. Invest. 123, 980–989 (2013).
61. Neckers, L. & Workman, P. Hsp90 molecular chaperone inhibitors: are we
there yet? Clin. Cancer Res. 18, 64–76 (2012).
62. Altieri, D. C., Stein, G. S., Lian, J. B. & Languino, L. R. TRAP-1, the
mitochondrial Hsp90. Biochim. Biophys. Acta 1823, 767–773 (2012).
63. Li, W., Sahu, D. & Tsen, F. Secreted heat shock protein-90 (Hsp90) in wound
healing and cancer. Biochim. Biophys. Acta 1823, 730–741 (2012).
64. Krukenberg, K. A., Bottcher, U. M., Southworth, D. R. & Agard, D. A. Grp94,
the endoplasmic reticulum Hsp90, has a similar solution conformation to
cytosolic Hsp90 in the absence of nucleotide. Protein Sci. 18, 1815–1827 (2009).
65. Sato, S., Fujita, N. & Tsuruo, T. Modulation of Akt kinase activity by binding to
Hsp90. Proc. Natl Acad. Sci. USA 97, 10832–10837 (2000).
66. Franke, T. F., Hornik, C. P., Segev, L., Shostak, G. A. & Sugimoto, C. PI3K/Akt
and apoptosis: size matters. Oncogene 22, 8983–8998 (2003).
67. Itoh, N. et al. Phosphorylation of Akt/PKB is required for suppression of cancer
cell apoptosis and tumor progression in human colorectal carcinoma. Cancer
94, 3127–3134 (2002).
68. Chen, J. et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the
activity of chemotherapeutic agents in vitro and in vivo. Mol. Cancer Ther. 10,
2340–2349 (2011).
69. Lazaro, I. et al. Targeting HSP90 ameliorates nephropathy and atherosclerosis
through suppression of NF-kappaB and STAT signaling pathways in diabetic
mice. Diabetes 64, 3600–3613 (2015).
70. Chilosi, M., Carloni, A., Rossi, A. & Poletti, V. Premature lung aging and
cellular senescence in the pathogenesis of idiopathic pulmonary ﬁbrosis and
COPD/emphysema. Transl. Res. 162, 156–173 (2013).
71. Tchkonia, T. et al. Fat tissue, aging, and cellular senescence. Aging Cell 9,
667–684 (2010).
72. Xu, M. et al. Transplanted senescent cells induce an osteoarthritis-like
condition in mice. J. Gerontol. A Biol. Sci. Med. Sci. 72, 780–785 (2016).
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00314-z ARTICLE
NATURE COMMUNICATIONS |8:  422 |DOI: 10.1038/s41467-017-00314-z |www.nature.com/naturecommunications 13
73. Niedernhofer, L. J. et al. The structure-speciﬁc endonuclease Ercc1-Xpf is
required to resolve DNA interstrand cross-link-induced double-strand breaks.
Mol. Cell Biol. 24, 5776–5787 (2004).
74. Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A simple statistical parameter for
use in evaluation and validation of high throughput screening assays. J. Biomol.
Screen. 4, 67–73 (1999).
75. Tchkonia, T. et al. Identiﬁcation of depot-speciﬁc human fat cell progenitors
through distinct expression proﬁles and developmental gene patterns. Am. J.
Physiol. Endocrinol. Metab. 292, E298–E307 (2007).
76. Ahmad, A. et al. ERCC1-XPF endonuclease facilitates DNA double-strand
break repair. Mol. Cell Biol. 28, 5082–5092 (2008).
Acknowledgements
We are grateful for the experimental support by Amira Barghouthy and Colten Lankford.
This work was supported by the NIH grants AG043376 (Project 2 and Core A: PDR,
Project 1 and Core B: LJN), AG13925 (JLK), DK50456 (JLK: Adipocyte Subcore), the
Connor Group and the Noaber, Ted Nash, and Glenn Foundations (JLK), the American
Federation for Aging Research (JLK), and Aldabra Biosciences (PDR and LJN).
Author contributions
The Scripps Research Institute: H.F.-S., Y.Y.L., R.W.B., A.D.G., and D.G. designed and
performed drug screening experiments with MEFs, MSCs, and IMR90s. P.T. performed
the senescent cell experiments with IMR90 cells. J.Z. and C.B. performed the RT-PCR
analyses on cells and mouse tissue. S.J.M. performed the in vivo studies with the help of
L.C. H.F.-S., L.J.N., and P.D.R. oversaw all experimental design, data analyses, and
prepared the manuscript. The Mayo Clinic: Y.Z. and T.T. designed and performed the
cell studies with HUVECs, T.T. and J.L.K. oversaw experimental design and data analyses
of HUVEC and pre-adipocyte data. University of Pittsburgh: S.Q.G. and J.L.S. performed
the initial characterization of senescent Ercc1−/− MEF. ICGEB, Trieste: N.R. designed and
performed the senescent cell studies with WI38 cells, M.G. oversaw the experimental
design and data analyses of human cell data.
Additional information
Supplementary Information accompanies this paper at doi:10.1038/s41467-017-00314-z.
Competing interests: Y.Z., T.T., and J.L.K. declare competing ﬁnancial interests. Patents
on certain senolytic drugs developed by Y.Z., T.T., and J.L.K. are held by Mayo Clinic and
have been licensed to Unity Biotechnology. This research has been reviewed by the Mayo
Clinic Conﬂict of Interest Review Board and was conducted in compliance with Mayo
Clinic Conﬂict of Interest policies. The remaining authors declare no competing ﬁnancial
interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2017
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00314-z
14 NATURE COMMUNICATIONS |8:  422 |DOI: 10.1038/s41467-017-00314-z |www.nature.com/naturecommunications
